LinkedIn Profile

Access NeuroNascent historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:neuronascent 8487705 Dec 3rd, 2020 12:00AM Neuronascent, Inc 75 3.00 Open Pharmaceuticals Dec 3rd, 2020 11:55AM Dec 3rd, 2020 11:55AM Neuronascent (NNI) is a small corporation, that we believe now has an over-sized opportunity to improve the well-being of millions of patients suffering from chronic neurodegenerative disorders that lack any disease-modifying therapeutic options. As we move toward this goal, we have built a strong track record of meeting critical drug-development milestones, of importance to investors and future pharmaceutical partners. Using a novel screening process developed by Neuronascent, the Company was able to identify small molecule therapeutics that generated new neurons in the brain and ensured that these new neurons survived to functionality under neurodegenerative conditions. These small molecule candidates proved successful not only on human neuronal progenitors in a lab dish, but showed the same capacity in animal models of chronic neurological diseases. NNI's synthetic therapeutic candidates are optimized and patented. These orally available candidates have been found to be safe in all testing to date. Our lead candidate for Alzheimer’s and potentially for Parkinson’s disease, is now in first-in-human testing (Phase 1a), to evaluate the safety of this therapeutic in healthy aged subjects. The Company is based in Clarksville, Maryland, United States. Open NeuroREgeneration, Neurorestoration, Small Molecules, Alzheimer's Disease, Parkinson's Disease, Down Syndrome, Fragile X Syndrome, Drug Development Open 6030 Daybreak Cir Clarksville Maryland US 21029-1642 NeuroNascent Health Care Pharmaceuticals & Biotechnology
private:neuronascent 8487705 Dec 2nd, 2020 12:00AM Neuronascent, Inc 75 3.00 Open Pharmaceuticals Dec 2nd, 2020 02:16PM Dec 2nd, 2020 02:16PM Neuronascent (NNI) is a small corporation, that we believe now has an over-sized opportunity to improve the well-being of millions of patients suffering from chronic neurodegenerative disorders that lack any disease-modifying therapeutic options. As we move toward this goal, we have built a strong track record of meeting critical drug-development milestones, of importance to investors and future pharmaceutical partners. Using a novel screening process developed by Neuronascent, the Company was able to identify small molecule therapeutics that generated new neurons in the brain and ensured that these new neurons survived to functionality under neurodegenerative conditions. These small molecule candidates proved successful not only on human neuronal progenitors in a lab dish, but showed the same capacity in animal models of chronic neurological diseases. NNI's synthetic therapeutic candidates are optimized and patented. These orally available candidates have been found to be safe in all testing to date. Our lead candidate for Alzheimer’s and potentially for Parkinson’s disease, is now in first-in-human testing (Phase 1a), to evaluate the safety of this therapeutic in healthy aged subjects. The Company is based in Clarksville, Maryland, United States. Open NeuroREgeneration, Neurorestoration, Small Molecules, Alzheimer's Disease, Parkinson's Disease, Down Syndrome, Fragile X Syndrome, Drug Development Open 6030 Daybreak Cir Clarksville Maryland US 21029-1642 NeuroNascent Health Care Pharmaceuticals & Biotechnology
private:neuronascent 8487705 Dec 1st, 2020 12:00AM Neuronascent, Inc 75 3.00 Open Pharmaceuticals Dec 1st, 2020 01:45PM Dec 1st, 2020 01:45PM Neuronascent (NNI) is a small corporation, that we believe now has an over-sized opportunity to improve the well-being of millions of patients suffering from chronic neurodegenerative disorders that lack any disease-modifying therapeutic options. As we move toward this goal, we have built a strong track record of meeting critical drug-development milestones, of importance to investors and future pharmaceutical partners. Using a novel screening process developed by Neuronascent, the Company was able to identify small molecule therapeutics that generated new neurons in the brain and ensured that these new neurons survived to functionality under neurodegenerative conditions. These small molecule candidates proved successful not only on human neuronal progenitors in a lab dish, but showed the same capacity in animal models of chronic neurological diseases. NNI's synthetic therapeutic candidates are optimized and patented. These orally available candidates have been found to be safe in all testing to date. Our lead candidate for Alzheimer’s and potentially for Parkinson’s disease, is now in first-in-human testing (Phase 1a), to evaluate the safety of this therapeutic in healthy aged subjects. The Company is based in Clarksville, Maryland, United States. Open NeuroREgeneration, Neurorestoration, Small Molecules, Alzheimer's Disease, Parkinson's Disease, Down Syndrome, Fragile X Syndrome, Drug Development Open 6030 Daybreak Cir Clarksville Maryland US 21029-1642 NeuroNascent Health Care Pharmaceuticals & Biotechnology
private:neuronascent 8487705 Nov 30th, 2020 12:00AM Neuronascent, Inc 74 3.00 Open Pharmaceuticals Nov 29th, 2020 07:49PM Nov 30th, 2020 02:37PM Neuronascent (NNI) is a small corporation, that we believe now has an over-sized opportunity to improve the well-being of millions of patients suffering from chronic neurodegenerative disorders that lack any disease-modifying therapeutic options. As we move toward this goal, we have built a strong track record of meeting critical drug-development milestones, of importance to investors and future pharmaceutical partners. Using a novel screening process developed by Neuronascent, the Company was able to identify small molecule therapeutics that generated new neurons in the brain and ensured that these new neurons survived to functionality under neurodegenerative conditions. These small molecule candidates proved successful not only on human neuronal progenitors in a lab dish, but showed the same capacity in animal models of chronic neurological diseases. NNI's synthetic therapeutic candidates are optimized and patented. These orally available candidates have been found to be safe in all testing to date. Our lead candidate for Alzheimer’s and potentially for Parkinson’s disease, is now in first-in-human testing (Phase 1a), to evaluate the safety of this therapeutic in healthy aged subjects. The Company is based in Clarksville, Maryland, United States. Open NeuroREgeneration, Neurorestoration, Small Molecules, Alzheimer's Disease, Parkinson's Disease, Down Syndrome, Fragile X Syndrome, Drug Development Open 6030 Daybreak Cir Clarksville Maryland US 21029-1642 NeuroNascent Health Care Pharmaceuticals & Biotechnology
private:neuronascent 8487705 Nov 28th, 2020 12:00AM Neuronascent, Inc 74 3.00 Open Pharmaceuticals Nov 28th, 2020 03:25PM Nov 28th, 2020 03:25PM Neuronascent (NNI) is a small corporation, that we believe now has an over-sized opportunity to improve the well-being of millions of patients suffering from chronic neurodegenerative disorders that lack any disease-modifying therapeutic options. As we move toward this goal, we have built a strong track record of meeting critical drug-development milestones, of importance to investors and future pharmaceutical partners. Using a novel screening process developed by Neuronascent, the Company was able to identify small molecule therapeutics that generated new neurons in the brain and ensured that these new neurons survived to functionality under neurodegenerative conditions. These small molecule candidates proved successful not only on human neuronal progenitors in a lab dish, but showed the same capacity in animal models of chronic neurological diseases. NNI's synthetic therapeutic candidates are optimized and patented. These orally available candidates have been found to be safe in all testing to date. Our lead candidate for Alzheimer’s and potentially for Parkinson’s disease, is now in first-in-human testing (Phase 1a), to evaluate the safety of this therapeutic in healthy aged subjects. The Company is based in Clarksville, Maryland, United States. Open NeuroREgeneration, Neurorestoration, Small Molecules, Alzheimer's Disease, Parkinson's Disease, Down Syndrome, Fragile X Syndrome, Drug Development Open 6030 Daybreak Cir Clarksville Maryland US 21029-1642 NeuroNascent Health Care Pharmaceuticals & Biotechnology
private:neuronascent 8487705 Nov 27th, 2020 12:00AM Neuronascent, Inc 74 3.00 Open Pharmaceuticals Nov 27th, 2020 11:50AM Nov 27th, 2020 11:50AM Neuronascent (NNI) is a small corporation, that we believe now has an over-sized opportunity to improve the well-being of millions of patients suffering from chronic neurodegenerative disorders that lack any disease-modifying therapeutic options. As we move toward this goal, we have built a strong track record of meeting critical drug-development milestones, of importance to investors and future pharmaceutical partners. Using a novel screening process developed by Neuronascent, the Company was able to identify small molecule therapeutics that generated new neurons in the brain and ensured that these new neurons survived to functionality under neurodegenerative conditions. These small molecule candidates proved successful not only on human neuronal progenitors in a lab dish, but showed the same capacity in animal models of chronic neurological diseases. NNI's synthetic therapeutic candidates are optimized and patented. These orally available candidates have been found to be safe in all testing to date. Our lead candidate for Alzheimer’s and potentially for Parkinson’s disease, is now in first-in-human testing (Phase 1a), to evaluate the safety of this therapeutic in healthy aged subjects. The Company is based in Clarksville, Maryland, United States. Open NeuroREgeneration, Neurorestoration, Small Molecules, Alzheimer's Disease, Parkinson's Disease, Down Syndrome, Fragile X Syndrome, Drug Development Open 6030 Daybreak Cir Clarksville Maryland US 21029-1642 NeuroNascent Health Care Pharmaceuticals & Biotechnology
private:neuronascent 8487705 Nov 26th, 2020 12:00AM Neuronascent, Inc 74 3.00 Open Pharmaceuticals Nov 26th, 2020 12:49PM Nov 26th, 2020 12:49PM Neuronascent (NNI) is a small corporation, that we believe now has an over-sized opportunity to improve the well-being of millions of patients suffering from chronic neurodegenerative disorders that lack any disease-modifying therapeutic options. As we move toward this goal, we have built a strong track record of meeting critical drug-development milestones, of importance to investors and future pharmaceutical partners. Using a novel screening process developed by Neuronascent, the Company was able to identify small molecule therapeutics that generated new neurons in the brain and ensured that these new neurons survived to functionality under neurodegenerative conditions. These small molecule candidates proved successful not only on human neuronal progenitors in a lab dish, but showed the same capacity in animal models of chronic neurological diseases. NNI's synthetic therapeutic candidates are optimized and patented. These orally available candidates have been found to be safe in all testing to date. Our lead candidate for Alzheimer’s and potentially for Parkinson’s disease, is now in first-in-human testing (Phase 1a), to evaluate the safety of this therapeutic in healthy aged subjects. The Company is based in Clarksville, Maryland, United States. Open NeuroREgeneration, Neurorestoration, Small Molecules, Alzheimer's Disease, Parkinson's Disease, Down Syndrome, Fragile X Syndrome, Drug Development Open 6030 Daybreak Cir Clarksville Maryland US 21029-1642 NeuroNascent Health Care Pharmaceuticals & Biotechnology
private:neuronascent 8487705 Nov 25th, 2020 12:00AM Neuronascent, Inc 74 3.00 Open Pharmaceuticals Nov 25th, 2020 06:20PM Nov 25th, 2020 06:20PM Neuronascent (NNI) is a small corporation, that we believe now has an over-sized opportunity to improve the well-being of millions of patients suffering from chronic neurodegenerative disorders that lack any disease-modifying therapeutic options. As we move toward this goal, we have built a strong track record of meeting critical drug-development milestones, of importance to investors and future pharmaceutical partners. Using a novel screening process developed by Neuronascent, the Company was able to identify small molecule therapeutics that generated new neurons in the brain and ensured that these new neurons survived to functionality under neurodegenerative conditions. These small molecule candidates proved successful not only on human neuronal progenitors in a lab dish, but showed the same capacity in animal models of chronic neurological diseases. NNI's synthetic therapeutic candidates are optimized and patented. These orally available candidates have been found to be safe in all testing to date. Our lead candidate for Alzheimer’s and potentially for Parkinson’s disease, is now in first-in-human testing (Phase 1a), to evaluate the safety of this therapeutic in healthy aged subjects. The Company is based in Clarksville, Maryland, United States. Open NeuroREgeneration, Neurorestoration, Small Molecules, Alzheimer's Disease, Parkinson's Disease, Down Syndrome, Fragile X Syndrome, Drug Development Open 6030 Daybreak Cir Clarksville Maryland US 21029-1642 NeuroNascent Health Care Pharmaceuticals & Biotechnology
private:neuronascent 8487705 Nov 24th, 2020 12:00AM Neuronascent, Inc 74 3.00 Open Pharmaceuticals Nov 24th, 2020 01:38PM Nov 24th, 2020 01:38PM Neuronascent (NNI) is a small corporation, that we believe now has an over-sized opportunity to improve the well-being of millions of patients suffering from chronic neurodegenerative disorders that lack any disease-modifying therapeutic options. As we move toward this goal, we have built a strong track record of meeting critical drug-development milestones, of importance to investors and future pharmaceutical partners. Using a novel screening process developed by Neuronascent, the Company was able to identify small molecule therapeutics that generated new neurons in the brain and ensured that these new neurons survived to functionality under neurodegenerative conditions. These small molecule candidates proved successful not only on human neuronal progenitors in a lab dish, but showed the same capacity in animal models of chronic neurological diseases. NNI's synthetic therapeutic candidates are optimized and patented. These orally available candidates have been found to be safe in all testing to date. Our lead candidate for Alzheimer’s and potentially for Parkinson’s disease, is now in first-in-human testing (Phase 1a), to evaluate the safety of this therapeutic in healthy aged subjects. The Company is based in Clarksville, Maryland, United States. Open NeuroREgeneration, Neurorestoration, Small Molecules, Alzheimer's Disease, Parkinson's Disease, Down Syndrome, Fragile X Syndrome, Drug Development Open 6030 Daybreak Cir Clarksville Maryland US 21029-1642 NeuroNascent Health Care Pharmaceuticals & Biotechnology
private:neuronascent 8487705 Nov 23rd, 2020 12:00AM Neuronascent, Inc 73 3.00 Open Pharmaceuticals Nov 23rd, 2020 03:39PM Nov 23rd, 2020 03:39PM Neuronascent (NNI) is a small corporation, that we believe now has an over-sized opportunity to improve the well-being of millions of patients suffering from chronic neurodegenerative disorders that lack any disease-modifying therapeutic options. As we move toward this goal, we have built a strong track record of meeting critical drug-development milestones, of importance to investors and future pharmaceutical partners. Using a novel screening process developed by Neuronascent, the Company was able to identify small molecule therapeutics that generated new neurons in the brain and ensured that these new neurons survived to functionality under neurodegenerative conditions. These small molecule candidates proved successful not only on human neuronal progenitors in a lab dish, but showed the same capacity in animal models of chronic neurological diseases. NNI's synthetic therapeutic candidates are optimized and patented. These orally available candidates have been found to be safe in all testing to date. Our lead candidate for Alzheimer’s and potentially for Parkinson’s disease, is now in first-in-human testing (Phase 1a), to evaluate the safety of this therapeutic in healthy aged subjects. The Company is based in Clarksville, Maryland, United States. Open NeuroREgeneration, Neurorestoration, Small Molecules, Alzheimer's Disease, Parkinson's Disease, Down Syndrome, Fragile X Syndrome, Drug Development Open 6030 Daybreak Cir Clarksville Maryland US 21029-1642 NeuroNascent Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.